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Small fragments circulating in the blood were formally identified by the end of the nine-
teenth century, and it was suggested that they assisted coagulation via interactions with
vessel endothelia. Wright, at the beginning of the twentieth century, identified their bone-
marrow origin. For long, platelets have been considered sticky assistants of hemostasis
and pollutants of blood or tissue samples; they were just cell fragments. As such, however,
they were acknowledged as immunizing (to specific HPA and HLA markers): the platelet’s
dark face. The enlightened face showed that besides hemostasis, platelets contained fac-
tors involved in healing. As early as 1930s, platelets entered the arsenal of medicines were
transfused, and were soon manipulated to become a kind of glue to repair damaged tis-
sues. Some gladly categorized platelets as cells but they were certainly not fully licensed
as such for cell physiologists. Actually, platelets possess almost every characteristic of
cells, apart from being capable of organizing their genes: they have neither a nucleus nor
genes.This view prevailed until it became evident that platelets play a role in homeostasis
and interact with cells other than with vascular endothelial cells; then began the era of
physiological and also pathological inflammation. Platelets have now entered the field of
immunity as inflammatory cells. Does assistance to immune cells itself suffice to license
a cell as an “immune cell”? Platelets prove capable of sensing different types of signals
and organizing an appropriate response. Many cells can do that. However, platelets can
use a complete signalosome (apart from the last transcription step, though it is likely that
this step can be circumvented by retrotranscribing RNA messages).The question has also
arisen as to whether platelets can present antigen via their abundantly expressed MHC
class I molecules. In combination, these properties argue in favor of allowing platelets the
title of immune cells.
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INTRODUCTION
It has become usual in the medicine and physiology community to
present platelets as “cells” that are indispensable to primary hemo-
stasis (their function in thrombosis is sometimes ignored); but still
today, it is not uncommon that representatives of the pathologist
community refute use of the word “cells” for platelets. Platelets, for
many, are dust or pollutants at worse, and cell debris at best, though
no one doubts their hemostatic functions. Two distinct arguments
may be considered in an attempt to explain their reluctance to
recognize platelets as cells:
1. Ex vivo, platelets usually “contaminate” histological prepara-
tions; because they have no nucleus and they apparently are
“solely” cytoplasm fractions, and platelets differ from cells
forming tissues and also from the regular blood cells: they
resemble impurities.
2. In vivo, platelet “puree,” and not mandatorily fresh, alive,
platelets within platelet components (PCs) for transfusion pur-
poses, can also achieve hemostasis in emergency conditions and
stop bleeding. This is how a large proportion of thawed PCs [a
type of blood component (BC) rarely used] behaves.
DISCOVERY OF PLATELETS AND THEIR FUNCTIONS
The initial discovery of platelets is disputed. Was Boyle (end of the
seventeenth century), Donné (early nineteenth century), or Biz-
zozzero (end of the nineteenth century) the real discoverer? It is
generally considered that the acknowledgment there is a third cel-
lular element in blood besides, and independent of, erythrocytes
and leukocytes, is attributed to Bizzozzero, around 1881–1882.
This Italian (Lombardy) physician and researcher also very ele-
gantly acknowledged the role of platelets not only in hemostasis
but also in thrombosis. Prior to Bizzozzero, and indeed as early as
the seventeenth century, platelets had been suspected. For instance,
van Leewenhoek, the Dutch microscopist who delivered amazing,
seminal observations of natural life, reported precise observa-
tions of platelets around 1675. Hewson (around 1780) reported
undefined blood particles. At that time, platelets bore names such
as particles, corpuscles, and globules. Important information on
their size, form change, granular content, and ability to emit fila-
ments was thus available quite early. However, at this time, platelets
were often considered to be of leukocyte origin and to be degen-
erate or degraded. Some observers favored an erythrocyte origin
(such as erythrocyte precursors or haemoblasts). Bizzozzero set up
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experiments to see platelets in veins, and also as circulating in the
mesentery of living animals. He found that they were unrelated to
erythrocytes and leukocytes, showed their role in hemostasis and
thrombosis, and predicted the intimate relationship of platelets
and leukocytes in the latter (and in other functions), as previ-
ously only leukocytes were visible in clots. The “only” discovery
that Bizzozzero did not make is the acknowledgment of the bone
marrow megakaryocyte ancestry of platelets, which Wright did in
1910 (1, 2).
WHY ARE PLATELETS SOMETIMES NOT RECOGNIZED AS
CELLS?
Platelets are non-nucleated cell elements that, clearly, result from
fractionation of bone marrow megakaryocytes (MKs). During dif-
ferentiation, MKs are exposed to constantly increasing pH and
pO2 until reaching the sinuses, where platelets are released from
proplatelets supported by shear from the blood flow. Expression
of CD34 decreases as MKs mature, while expression of CD41 and
CD42b increases (3). In the final step of MK development, platelets
are released, and MK cytoskeletal reorganization is an impor-
tant intracellular process for these morphologic changes. The
correlation between cytoskeleton reorganization and proplatelet
formation has not been completely clarified. Serotonin is thought
to modulate cell migration and remodeling through activation of
cytoskeleton reorganization, depending on the Rho/ROCK and
Erk1/2 pathways, and 5HT1A/1B/1D and 5HT4 receptors (4).
As such, platelets contain (inherit) MK cytoplasm complete
with granules, mitochondria, and mRNA. Indeed, anucleate
platelets lack genomic DNA but inherit a diverse array of func-
tional coding or non-coding RNAs and translational machinery
from their parent cells, enabling activated platelets to synthesize
proteins, which suggests the possibility of post transcriptional
gene regulation in platelets (5–8). The soluble proteins stored in
the α-granule matrix, such as von Willebrand factor and throm-
bospondin, are derived via exclusive synthesis in the MKs, or for
proteins such as fibrinogen and albumin, through endocytosis of
plasma proteins (9).
Thus,platelets resemble cell fragments rather than fully licensed
cells. One of the strongest arguments is probably that platelets
have no genes to reorganize, because they have no nucleus
and supporting DNA material (apart from the mitochondrial
genome).
What about comparison with erythrocytes? Erythrocytes are
not denied the qualification of cells though they have neither
a nucleus nor genes to reorganize. However, the non-nucleated
status of erythrocytes only pertains to mammals, not birds or
reptiles. Erythrocytes in mammals evolved from erythroblasts,
which are nucleated, and the process of enucleation is finite: one
nucleated erythroblast gives rise to one erythrocyte with no inter-
mediate division or transformation (10, 11). MKs, when forced
to terminal maturation, separate into a degraded nucleus and
platelets, emphasizing the nature of platelets, which are “only”
cytoplasm fragments. An MK may produce 10–20 proplatelets,
each of which starts as a blunt protrusion that over time elon-
gates, thins, and branches repeatedly. The proplatelets extend into
sinusoidal spaces, where they detach and fragment into individual
platelets, giving rise to about 2000–5000 new platelets. Each day,
in every human, approximately 1× 1011 platelets are produced by
the cytoplasmic fragmentation of MKs (12–15).
Although it is well established that platelets originate from MKs,
the mechanisms by which they are formed and released remains
controversial. Three models of platelet formation have been pro-
posed: (1) cytoplasmic fragmentation, (2) platelet budding, and
(3) proplatelet formation (13, 16, 17).
One must note that this classical picture of thrombopoiesis
is unique (if one accepts the long-debated possibility that there
is extramedullary thrombopoiesis, possibly in the lung). It has,
however, recently been shown that there is a modest but definite
thrombopoiesis in the circulation, as platelets give rise them-
selves to buds and extrusions distinct from platelet micro-particles
(PMPs), turning into pro- and then pre-platelets (5–8, 18, 19).
This is not a characteristic of a cell fragment without autonomy.
This is, if further evidence is needed, a very strong argument
in favor of platelets’ classification as cells. Platelets also form
the link between thrombosis and inflammation through the pro-
duction of microparticles (MPs). PMPs are phospholipid vesicles
(100–1000 nm) released after budding from the platelet plasma
membrane. Platelets shed these membrane vesicles after stimu-
lation with physiological agonists such as thrombin or collagen,
in response to high shear stress (e.g., in severe stenosis) or in the
presence of danger signals. As a result, PMP express the same anti-
gens as their parent cells, i.e., GPIIb–IIIa, GPIb, CD31, CD61, and
CD62P. This distinguishes them from MPs derived from other cell
types (red blood cells, leukocytes, monocytes, endothelial cells).
PMPs thus make up between 70 and 90% of the circulating vesi-
cles. PMPs differ from exosomes by their size, and also due to the
fact that they are not derived from exocytosis of multivesicular
bodies (20–24).
PLATELETS BEHAVE AS CELLS
Platelets share some very important properties of cells. We list nine
here – in physiological order of appearance – but there are many
more.
1. Platelets display receptors for a variety of moieties, collectively
termed “stimuli,” but individually are quite different in nature.
Platelets have glycoproteins (GPs) that sense exposed vascu-
lar sub-endothelium structures after vessel stress, insult, or
attrition (including mechanical erosion and aging). Platelets
can sense non-self infectious danger signals via a panoply of
receptors detailed in a companion article. Platelets also display
alarmins that can sense self-injury (25–27).
2. Platelets can respond to soluble molecules, via their recep-
tors, and this can be particularly evidenced for thrombin or
thrombin-derived peptides; hence, platelets are reactive to ago-
nists and also to antagonists of such hemostatic/thrombotic
factors. Additionally, platelets can react to biological response
modifiers (BRMs) such as cytokines and chemokines, and
become activated or inhibited. Some new drugs and biologics
exploit those discerning properties (28–36).
3. Platelets comprise a complete and functional signalosome.
Upon stimulation, they can phosphorylate a cascade of signal-
ing molecules upstream of NFkB. NFkB is a crucial molecule
in platelet physiology (37–42).
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4. The platelet proteome is currently being investigated to deter-
mine the effects of treatments inflicted on platelets, such as
for PC processing prior to transfusion. It is quite impressive,
with more than 1000 proteins currently identified, and more
being discovered regularly; 300–350 of those proteins have been
proven as secreted by platelets (43). Platelet originating pro-
teins come from three origins: (i) they may be inherited from
the MK, (ii) they are absorbed from neighboring fluids and
especially plasma [platelets have been described as “sponges”
(44)], and (iii) they can be produced de novo, using a retrotran-
scription RNA process and spliceosome. This latter property
further justifies the qualification of “cell” for platelets (45–51).
5. Platelets are docked with proteins/GPs for several, and dis-
tinct, purposes, including hemostasis, thrombosis, sensing, nat-
ural anti-infection (bacterial, viral, perhaps fungal) defense,
chemo-attraction, cell communication, angiogenesis, healing,
and tissue repair. It is clear, though under-evaluated in terms
of physiological value, that platelets make distinction among
the “dangers” they face. They can decipher vascular insult and
presence of (circulating) infectious pathogens or components
of the microbiota (infectious or not, an area that has not yet
been examined in-depth), and secrete discrete, probably best-
fitted, assortments of “products,” likely coming into “profiles”
of BRMs (34, 52–55). This has been well-studied in the case
of innate immunity to bacterial products (and live bacteria
as well), using the TLR1, TLR2, TLR3, TLR4, TLR6, TLR7,
and TLR9 pattern recognition receptors (PRRs) (33, 35, 56–
65): platelets can sense distinct natures of danger and secrete
different patterns of BRMs accordingly. For instance, LPS, tar-
geting TLR4, was shown to stimulate a distinct intracellular
signaling pathway, and elicit the secretion of distinct profiles
of BRMs (54, 55). Therefore, platelets are “intelligent” in that
they effectively sense the nature of a given danger and respond
accordingly.
6. It has been reported recently that platelets have novel func-
tions in vascular permeability. Certain among these have been
revealed in pathology; hence, platelets and their PMPs occa-
sionally infiltrate tissues and cause attrition and inflammation
(66). Platelets have recently been identified as being largely
responsible for the discerned control of vascular permeabil-
ity, with extravasation of lymphocytes, activated as effectors of
immunity, but not erythrocytes because they otherwise warrant
the sealing of the vascular arborescence (which is the primary
role of platelets) (67). Platelets have also been reported novel
roles in pathology: they make leukocytes prone to release neu-
trophil extracellular traps (NETs) with functions in infection
(e.g., sepsis) and also in cancer, favoring thrombosis in either
case (68–70).
7. Platelets can bind pathogens. Platelets can sense infectious
pathogens and in certain occasion bind to them, sometimes
tightly, either directly or indirectly as immune complexes with
antibodies or complement factors such as C5a. In vitro, C5b–9
is capable of inducing P-selectin expression on platelets, and
both C5a and C5b–9 induce surface expression of P-selectin on
endothelial cells (71–74).
8. For reasons yet unclear, some infectious pathogens can enter
platelets and at least reside in them. The issue of platelet
“infection” is largely unstudied, as well as the outcome of the
infected platelets. The relationship between platelets and infec-
tious pathogens has been described in recent reviews (29, 30,
35, 75–81).
9. Platelets have one of the shortest lifespan among all human
cells (only certain epithelial cells are comparable to them, if one
excepts the granulocytes, which dye shortly from functioning
as phagocytes): this property has probably contributed to deny
the “cellularity” of platelets. Platelets die as a consequence of
different causes/mechanisms. Leytin (82) clearly described all
events of platelet death by apoptosis, but Jackson and Schoen-
waelder (83) uses the term senescent platelet death rather than
apoptosis stricto sensu. All events of activation-associated death
are necrosis, since activation-associated platelet death results in
improved inflammatory receptors, release of BRMs and aggre-
gation that causes immune reactions. Because platelets are
anucleate, their apoptosis leading to cell death is intriguing
(82). Two main pathways were reported, (i) intrinsic and (ii)
extrinsic, that are highly regulated by intra-platelet signaling
mechanisms (84). Platelet apoptosis might also play a role in
hemostasis, thrombosis, and inflammatory processes (84, 85).
The cellular functions of platelets are cartooned in Figure 1
(Figure 1A gives a broad picture of the cellular functions of
platelets, while Figure 1B details one selected platelet activation
pathway from the sensing of a danger signal on the surface to the
phosphorylation of NFκB (54) [NF-κB is a protein complex that
usually controls transcription of DNA in Eukaryotes. NF-κB is
found in almost all cell types involved in cellular responses to an
extremely large variety of stimuli; it has NF-κB a key role in regu-
lating the immune response to infection and – in turn – incorrect
regulation of NF-κB has been linked to cancer, inflammatory, and
autoimmune diseases, septic shock, viral infection, and improper
immune development; it is also implicated in plasticity and cell
survival (86)].
PLATELETS AS IMMUNE CELLS
What are “immune cells”? There is neither clear nor definite def-
inition of an immune cell. A recent NIAID document states that:
“The immune system stockpiles a huge arsenal of cells, not only lym-
phocytes but also cell-devouring phagocytes and their relatives. Some
immune cells take on all intruders, whereas others are trained on
highly specific targets. To work effectively, most immune cells need
the cooperation of their comrades. Sometimes immune cells commu-
nicate by direct physical contact, and sometimes they communicate
releasing chemical messengers [. . .]”1. According to that, platelets
would be acknowledged as immune cells, but this document next
stipulates that: “All immune cells begin as immature stem cells in the
bone marrow. They respond to different cytokines and other chemical
signals to grow into specific immune cell types [. . .]”1; this addition
would thus next deny the attribute of “immune” cell to platelets,
as they do not transform themselves. Well considered, this defini-
tion does not, either, take into consideration cells and organs that
are now known as being essential to optimal immune functioning,
1http://www.niaid.nih.gov/topics/immunesystem/Pages/immuneCells.aspx
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FIGURE 1 | (A) Platelets possess important secretory functions, express
internal membrane proteins, and release adhesive proteins, coagulation,
and growth factors. Certain of the proteins facilitate the cross-talk of
platelets with immune (e.g., leukocytes) and non-immune cells (e.g.,
endothelial cells). Thus, platelets play and important role in inflammatory
and proliferative events and play a critical role for tissue remodeling and
wound healing. (B) Human platelets can discriminate between various
bacterial LPS isoforms via TLR4 signaling and differential cytokines
secretion [adapted from Berthet et al. (54) and Hamzeh-Cognasse et al.
(87)].
such as the microbiota for example. One may this consider that
besides to key cellular actors (“Stars”) of immunity such as the
lymphocytes, the phagocytes and the Ag presenting cells, there
are “Supporting – though essential – roles” on stage, that are cells,
which participate to immunity (such as endothelial cells, epithelial
cells, and platelets).
The issue of platelets as “immune” cells has thus been not only
endorsed but also extensively covered recently in a number of
excellent review articles (33, 48, 88–90); therefore, we present only
a brief overview and select three representative issues to address
the question of platelet cellularity.
1. Platelets are innate immune sensors. As has been already pre-
sented, platelets display on their surface, and up-regulate upon
stimulation, PRRs: hallmarks of innate immune functioning,
beginning with the sensing of danger (28, 33, 35, 54). This
property allows platelets to deal with infectious pathogens, with
different outcomes depending on the nature of the invader (76,
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78, 79, 81, 91–103). Platelets’ relationships with germs from the
microbiota at the mucosal surfaces are suspected, but not yet
deciphered.
2. Doing so, the platelets initiate inflammation. We, in fact, believe
platelets are definitely inflammatory cells that exert their prin-
cipal role in the physiology of vessel endothelium by detecting
(sensing) dangers (vascular insults and attritions) and by fixing
damage on a permanent basis. This physiological interven-
tion and repair are no less than a healing process, which itself
relates to physiological inflammation. To assist this physiologi-
cal inflammation, platelets produce assortments of repair tools,
such as clotting factors, cytokines, and other BRMs, growth
factors, and angiogenic factors (23, 35, 75, 104–108). Apart
from taht, platelets can surpass their physiological role and
participate in pathological inflammation, as with cardiovascu-
lar disease, severe infection and sepsis, and arthritis (18, 23,
29, 31, 32, 36, 75, 105, 106, 109–117). Platelets, when trans-
fused as PCs, exert their physiological and repairing role, but
in 2–3% of cases (118), the physiological barrier is overcome
and they release significant amounts of pro-inflammatory and
directly inflammatory factors from the α and δ granules, and
membrane-bound as well as solubilized or cleaved molecules.
They also secrete in certain cases pro-allergenic factors (from
the δ granules).
3. Platelets assist innate immunity and affect adaptive immune
cells. The very first interactive role of platelets with other
blood cells was, again, discovered nearly 140 years ago, with
the interplay between platelets and leukocytes in thrombosis.
Platelets also have extensive, though complex, interplay with
leukocytes and especially polymorphonuclear cells (granulo-
cytes) in increasing, among other things, NETs (95, 119–123).
Platelets also activate monocytes and macrophages (109, 115,
124–126), T cells (127–129), B cells (28, 130–135), NK cells
(136–138), and dendritic cells (DCs) (87, 93, 139–144). In turn,
platelets can be activated by monocytes, T cells, B cells, and DCs
(87, 89, 132, 145). This mutual interaction is not anecdotic
since, for example, activated platelets can alter the isotype (Ig
class) switch program of differentiated B cells (132). Moreover,
platelets that harbor numerous copies of HLA class I mole-
cules (~100,000 copies per cell) have been proposed as antigen
presenting cells (this discovery, however, awaits firmer con-
firmation) (146). It has otherwise been suggested that more
MHC-I is absorbed from the plasma by the platelets, than is
derived from the platelet itself (33). Chapman et al. indicated
that platelets always express significant amounts of MHC-I,
but that this expression significantly increases during infection
(146). Of note, those HLA class I molecules, along with variant
moieties harbored by the GP molecules that mediate platelet
adhesion and aggregation, termed human platelet antigens or
HPA, display polymorphisms that render one’s platelets pos-
sibly immunizing when transfused into a recipient’s body (or
from the fetus to the mother) (147).
In sum, platelets are not only innate and inflammatory cells
themselves, but they can also assist, depending on the circum-
stances, adaptive immunity. They do not only assist immunity as
has long been thought, but are immune cells.
CONCLUDING REMARKS
There is no longer doubt that platelets are cells. They are also
“intelligent” in that they are capable of discriminating between
several types of danger and of adjusting a secretory response. This
response is in general, physiologically, only that which is needed to
face the danger or to fix a limited insult. This is indeed a platelet’s
usual function, and what they do when they repair daily the vas-
cular endothelium that they patrol is detect cracks and erosions,
and prevent breaches and leakage (bleeding). However, the nature
or extent of secretory responses by activated platelets occasion-
ally surpasses physiological conditions and becomes pathogenic.
This suggests susceptibility factors in individuals or in transfused
patients, along with favorable conditions linked to causal dis-
eases and/or therapeutics. This last issue is now regarded with
renewed interest because platelet actions can be easily manipulated
by drugs. If correctly readdressed, platelet activation can be turned
from deleterious to beneficial to the patient in a range of different
infectious and inflammatory situations such as cardiovascular dis-
ease, serious infections, autoimmune disorders, autoinflammatory
diseases, and cancer.
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